The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://jasonlfog996937.look4blog.com/76605759/retatrutide-vs-tirzepatide-a-comparative-analysis